Calidi Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
Calidi Biotherapeutics, Inc. (CLDI), a Delaware corporation, filed this Current Report on Form 8-K on November 14, 2023. The filing serves to disclose the Company's financial and operational results for the third quarter ended September 30, 2023, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release (Exhibit 99.1) but are not present in the source text provided.
Material Changes
No specific material changes versus the prior comparable period are detailed in this filing text. The document solely announces the issuance of the Q3 2023 results.
Guidance, Outlook, and Risks
The filing incorporates Regulation FD disclosure regarding the Q3 results. It explicitly states that the information furnished under Items 2.02 and 7.01, including the press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings. No specific guidance, outlook, or risk factors are detailed in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 14, 2023) for actual Q3 2023 financial figures.
- Verify the Company's cash position and burn rate, as these are critical for a pre-revenue biotech firm but are not listed in this summary text.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.